3 Grants Across Danish and EU programmes 

Wenemea is a Danish startup with a vision to continuously develop and accelerate the technology that reduce nerve damage following chemotherapy through neurological screening. Wenemea has followed a structured project financing strategy developed in close collaboration with Nordic Innovators as its trusted advisor. The strategy has secured three successive grants across both national and EU funding schemes. 

A Winning Funding Strategy 

Wenemea’s funding journey reflects a clear and well-defined roadmap supporting the continuous advancement of its Chemotherapy-Induced Peripheral Neuropathy (CIPN) device and AI model

The collaboration between Wenemea and Nordic Innovators began by identifying Wenemea’s ’s financing needs and development stage followed by defining the funding strategy with programme recommendations and a timeline to maximise their financing potential.

This led to the first successful grant in 2023 from the Danish Innobooster programme focused on validating the technology and build a foundation for future scaling. The initial project explored the measurement of nerve damage in elderly fall patients where high precision was not yet critical.

Building on these results, Wenemea secured a second successful Innobooster grant in 2025 to further develop the technology. It became clear that there was a need to measure even weaker cutaneous nerve signals particularly relevant for detecting nerve damage following surgical procedures - requiring a substantial increase in measurement accuracy.

From National to European Grant Success

In parallel with national funding, we also supported Wenemea in expanding its activities internationally by securing Eurostars funding in 2025, marking the company’s transition into a cross-border R&D collaboration. 

The Eurostars project focuses on Chemotherapy-Induced Peripheral Neuropathy (CIPN), a common side effect of chemotherapy, particularly in breast cancer treatment. The project aims to enable highly precise measurements for early detection, optimise chemotherapy treatment, and ultimately reduce long-term patient harm.

Wenemea is a great example of how a solid funding strategy can support SMEs through the different stages of technology development from first versions to increasingly specialised use cases.